These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10807046)

  • 1. Immune privilege or inflammation? The paradoxical effects of Fas ligand.
    O'Connell J
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):73-9. PubMed ID: 10807046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
    Kim R; Emi M; Tanabe K; Uchida Y; Toge T
    Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas/Apo-1 (CD95)-mediated apoptosis of neutrophils with Fas ligand (CD95L)-expressing tumors is crucial for induction of inflammation by neutrophilic polymorphonuclear leukocytes associated with antitumor immunity.
    Shimizu M; Fontana A; Takeda Y; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jan; 207(1):41-8. PubMed ID: 11161452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
    Zhang H; Yang Y; Horton JL; Samoilova EB; Judge TA; Turka LA; Wilson JM; Chen Y
    J Clin Invest; 1997 Oct; 100(8):1951-7. PubMed ID: 9329958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
    Shukuwa T; Katayama I; Koji T
    Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Fas signalling pathway and its role in the pathogenesis of cancer.
    Houston A; O'Connell J
    Curr Opin Pharmacol; 2004 Aug; 4(4):321-6. PubMed ID: 15251123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
    Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells.
    Fujino M; Li XK; Suda T; Hashimoto M; Okabe K; Yaginuma H; Mikoshiba K; Guo L; Okuyama T; Enosawa S; Amemiya H; Amano T; Suzuki S
    Xenotransplantation; 2001 May; 8(2):115-24. PubMed ID: 11328582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas/Fas ligand system and apoptosis induction in testicular carcinoma.
    Schmelz HU; Abend M; Kraft K; Hauck EW; Weidner W; Van Beuningen D; Sparwasser C
    Cancer; 2002 Jul; 95(1):73-81. PubMed ID: 12115319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation.
    Matter CM; Chadjichristos CE; Meier P; von Lukowicz T; Lohmann C; Schuler PK; Zhang D; Odermatt B; Hofmann E; Brunner T; Kwak BR; Lüscher TF
    Circulation; 2006 Apr; 113(15):1879-87. PubMed ID: 16606788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas receptor-mediated apoptosis: a clinical application?
    Timmer T; de Vries EG; de Jong S
    J Pathol; 2002 Feb; 196(2):125-34. PubMed ID: 11793363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover.
    French LE; Tschopp J
    Behring Inst Mitt; 1996 Oct; (97):156-60. PubMed ID: 8950473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Fas and FasL as mediators of anticancer chemotherapy.
    Poulaki V; Mitsiades CS; Mitsiades N
    Drug Resist Updat; 2001 Aug; 4(4):233-42. PubMed ID: 11991678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of placental Fas ligand in maintaining immune privilege at maternal-fetal interfaces.
    Guller S; LaChapelle L
    Semin Reprod Endocrinol; 1999; 17(1):39-44. PubMed ID: 10406074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.